menu
    • menu

    Company profile for Dyne Therapeutics

    NEW Drugs in Dev: 5
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dyne TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Technology Square 10th Floor Cambridge, MA, 02139
    Telephone
    Telephone
    (508) 277-8117
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dyne-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dynetx
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/dyne_tx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dyne Files BLA for Z-Rostudirsen in Exon 51 Duchenne MD
    Dyne Files BLA for Z-Rostudirsen in Exon 51 Duchenne MD

    26 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/26/3300969/0/en/dyne-therapeutics-announces-submission-of-biologics-license-application-bla-to-u-s-fda-for-z-rostudirsen-in-exon-51-duchenne-muscular-dystrophy-dmd.html

    GLOBENEWSWIRE
    26 May 2026
    Share Share
    Regenxbio, Novartis & Dyne Near FDA Filing for Muscular Dystrophy
    Regenxbio, Novartis & Dyne Near FDA Filing for Muscular Dystrophy

    26 May 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/regenxbio-novartis-dyne-near-fda-submissions-in-muscular-dystrophies

    BIOSPACE
    26 May 2026
    Share Share
    Dyne Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
    Dyne Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    20 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/20/3298933/0/en/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

    GLOBENEWSWIRE
    20 May 2026
    Share Share
    Dyne Therapeutics Initiates Phase 3 Forzetto Trial in DMD
    Dyne Therapeutics Initiates Phase 3 Forzetto Trial in DMD

    20 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/20/3298383/0/en/dyne-therapeutics-announces-initiation-of-phase-3-forzetto-trial-of-z-rostudirsen-in-duchenne-muscular-dystrophy-dmd-ahead-of-planned-bla-submission-for-u-s-accelerated-approval.html

    GLOBENEWSWIRE
    20 May 2026
    Share Share
    Dyne Therapeutics To Participate In Upcoming Investor Conferences
    Dyne Therapeutics To Participate In Upcoming Investor Conferences

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293878/0/en/dyne-therapeutics-to-participate-in-upcoming-investor-conferences.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Dyne Therapeutics Unveils Q1 2026 Financials And Business Updates
    Dyne Therapeutics Unveils Q1 2026 Financials And Business Updates

    11 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/11/3291782/0/en/dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights.html

    GLOBENEWSWIRE
    11 May 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search